AstraZeneca PLC

AstraZeneca PLC is a Swedish-British multinational pharmaceutical and biotechnology company headquartered at the Cambridge Biomedical Campus in the United Kingdom. Formed in 1999 through the merger of Sweden's Astra AB and the UK's Zeneca Group, it develops, manufactures, and commercializes innovative prescription medicines addressing major global health challenges. The company's robust portfolio spans key therapeutic areas including **oncology**, where it advances next-generation cancer treatments; **cardiovascular, renal, and metabolic diseases**; **respiratory and immunology**, targeting asthma, COPD, and immune-driven conditions; as well as rare diseases, neuroscience, infection, and inflammation. Notable products include Nexium for gastrointestinal issues, Tagrisso for lung cancer, and contributions to COVID-19 vaccines. With major R&D hubs in Cambridge, Gothenburg, and Gaithersburg, AstraZeneca employs around 90,000 people across 85 countries, driving scientific breakthroughs through strategic acquisitions like MedImmune and partnerships. Its global operations emphasize patient-centric innovation, sustainability, and access initiatives such as Healthy Heart Africa, solidifying its role as a leader in biopharmaceuticals.